Compare GOLF & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOLF | TVTX |
|---|---|---|
| Founded | 1910 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | 2016 | 2013 |
| Metric | GOLF | TVTX |
|---|---|---|
| Price | $89.19 | $46.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $83.67 | $40.62 |
| AVG Volume (30 Days) | 314.2K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $1,633,721,000.00 | N/A |
| Revenue This Year | $5.76 | $44.76 |
| Revenue Next Year | $2.44 | $35.51 |
| P/E Ratio | $65.43 | ★ N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $69.54 | $13.88 |
| 52 Week High | $104.81 | $48.61 |
| Indicator | GOLF | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 58.73 |
| Support Level | $88.33 | $41.43 |
| Resistance Level | $92.18 | $48.60 |
| Average True Range (ATR) | 2.22 | 2.02 |
| MACD | 0.35 | -0.24 |
| Stochastic Oscillator | 55.39 | 65.70 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.